This FTSE 250 dividend growth stock isn’t the first share I’d buy despite today’s positive news

These FTSE 250 (INDEXFTSE: MCX) companies could offer strong dividend potential in the long term.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With interest rates set to remain at relatively low levels over the coming years in a period of continued monetary policy tightening, buying dividend shares could be a shrewd move. Other assets may gradually become more appealing on an absolute basis, but they may fail to outperform shares when it comes to income returns.

Reporting on Thursday was a FTSE 250 dividend growth stock which seems to offer a strong income future. However, it may not be the most appealing dividend play in the mid-cap index at the present time.

Solid performance

Releasing a first quarter trading update on Thursday was aqueous polymer specialist Synthomer (LSE: SYNT). Trading during the period has been relatively consistent, with its Europe and North America segment delivering higher volumes than in the comparative period. This was largely due to the positive impact of the Speciality Additives and Pischelsdorf SBR latex acquisitions.

Similarly, the company’s performance in Asia and the Rest of World segment was in line with expectations. Nitrile latex volumes were marginally higher than in the weaker comparative period when customer spending was hurt by a volatile raw material environment. This has helped the business to remain on track to meet its guidance for the full year.

With Synthomer forecast to deliver earnings growth of 5% in the current year and a further 10% next year, it seems to be performing well. This should enable it to raise dividends per share by around 7% per annum during the next two years, which puts it on a forward dividend yield of 2.8%. Since dividends are covered 2.5 times by profit, they could rise rapidly over the medium term and improve the company’s income outlook.

Low valuation

While Synthomer appears to offer an upbeat dividend future, fellow FTSE 250-listed company Crest Nicholson (LSE: CRST) could offer an even more compelling income investment outlook. The housebuilder has a dividend yield of over 7% at the present time, with further dividend growth forecast over the next two years.

The company is expected to report a rise in earnings of 6% this year, followed by additional growth of 12% in the 2019 financial year. These figures should enable dividend growth of over 10% per annum during the same time period, which could lead to a dividend yield of over 8% next year.

Clearly, the housebuilding sector faces an uncertain future and Crest Nicholson’s share price could prove to be highly volatile. However, with the company’s dividend being covered twice by profit and it trading on a price-to-earnings (P/E) ratio of around 8, it seems to offer a wide margin of safety.

Therefore, for long-term income investors who are comfortable with the potential for above-average volatility in the short term, it could prove to be a sound risk/reward opportunity at the present time. Its low valuation plus high dividend growth prospects could mean it is able to justify a higher share price in future years.

Peter Stephens owns shares of Crest Nicholson. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »